KRKA - Decision of the Patents Court in London relating to Esomeprazole

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 15 / 2014

Date of issue: 2014-04-07

Short name of the issuer

KRKA

Subject

Decision of the Patents Court in London relating to Esomeprazole

Official market - legal basis

Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne

Unofficial market - legal basis

Contents of the report:

Krka d.d., Novo mesto (hereafter referred to as Krka) is informing the public that Krka has received the decision of the High Court of Justice, Patents Court in London in the tort proceeding between by AstraZeneca AB, ©vedska and AstraZeneca UK Limited (hereinafter collectively referred to as AstraZeneca) in which Krka and its UK partner requested damages because of interim injunction which prevented sales of Krka’s Esomeprazole in the UK between mid-2010 and mid-2011, for alleged infringement of AstraZeneca's patent EP 1 020 461. Krka will receive damages and legal costs in an amount of approx. 21,000,000 EUR. The decision is not final. AstraZeneca can file an appeal against the decision.

Annexes

File Description

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

8501 Nove Mesto

(post code) (city)

Smarjeska 6

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

SI82646716

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2014-04-07 Jo¾e Colariè President of the Management Board